Citigroup Analyst Gives Solid Biosciences a Buy Rating with 16 Price Target
Citigroup analyst David Hoang has just released a report on Solid Biosciences (NASDAQ: SLDB) on March 15, 2024. Hoang has ...
Tag: SLDB
Groundbreaking Licensing Agreement to Develop RNAi Therapy for FSHD
Solid Biosciences and Armatus Bio have joined forces in a groundbreaking licensing agreement on March 7, 2024. This collaboration will ...
Solid Biosciences Inc Receives Orphan Drug Designation for Groundbreaking Gene Therapy to Combat Duchenne Muscular Dystrophy
On January 16, 2024, Solid Biosciences Inc. received an orphan drug designation (ODD) from the U.S. Food and Drug Administration ...
Popular News
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
-
NextGen Healthcare Charts Course for Behavioral Health Transformation
-
Regulatory Shift Sparks Potential Breakthrough for DeFi Technologies
